VanEck China Growth Leaders ETF (GLCN)
- Previous Close
21.36 - Open
21.08 - Bid 8.46 x 1000
- Ask --
- Day's Range
21.08 - 21.08 - 52 Week Range
21.08 - 29.39 - Volume
1,262 - Avg. Volume
675 - Net Assets 12.19M
- NAV 21.24
- PE Ratio (TTM) 7.99
- Yield 2.59%
- YTD Daily Total Return -13.70%
- Beta (5Y Monthly) 0.67
- Expense Ratio (net) 0.60%
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index and/or in investments that have economic characteristics that are substantially identical to the economic characteristics of the securities that comprise its benchmark index. The index is comprised of Chinese equity securities which are generally considered by the index provider to exhibit favorable fundamental characteristics according to its proprietary scoring methodology.
VanEck
Fund Family
China Region
Fund Category
12.19M
Net Assets
2010-10-13
Inception Date
Performance Overview: GLCN
Trailing returns as of 10/3/2023. Category is China Region.
Holdings: GLCN
Top 10 Holdings (40.64% of Total Assets)
Sector Weightings
Recent News: GLCN
Research Reports: GLCN
SCVL: Rating decreased to a HOLD
SHOE CARNIVAL INC has an Investment Rating of HOLD; a target price of $23.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetSCVL: Raising target price to $26.00
SHOE CARNIVAL INC has an Investment Rating of BUY; a target price of $26.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetCHRS: What does Argus have to say about CHRS?
COHERUS BIOSCIENCES INC has an Investment Rating of SELL; a target price of $4.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetCHRS: What does Argus have to say about CHRS?
COHERUS BIOSCIENCES INC has an Investment Rating of SELL; a target price of $4.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice Target